Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
May 14, 2024 10:30 ET
|
Disc Medicine Inc
Additional analyses of data from AURORA, as well as the full adult data set from BEACONUpdated data from the ongoing Phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia, including a...
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
May 13, 2024 08:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 08:00 ET
|
Disc Medicine Inc
Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024On track to deliver additional analyses from BEACON and...
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
April 01, 2024 08:00 ET
|
Disc Medicine Inc
Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light...
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024 08:00 ET
|
Disc Medicine Inc
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024On track to deliver multiple read-outs in 2024,...
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
March 06, 2024 16:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
February 26, 2024 08:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
February 20, 2024 08:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
February 09, 2024 09:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
February 07, 2024 08:00 ET
|
Disc Medicine Inc
Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at both development and commercial-stage...